NATCO Pharma is currently trading at Rs. 852.55, up by 29.05 points or 3.53% from its previous closing of Rs. 823.50 on the BSE.
The scrip opened at Rs. 880.05 and has touched a high and low of Rs. 880.05 and Rs. 845.50 respectively. So far 34316 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1340.45 on 07-Feb-2025 and a 52 week low of Rs. 660.05 on 07-Apr-2025.
Last one week high and low of the scrip stood at Rs. 880.05 and Rs. 808.00 respectively. The current market cap of the company is Rs. 15260.16 crore.
The promoters holding in the company stood at 49.48%, while Institutions and Non-Institutions held 20.54% and 29.97% respectively.
NATCO Pharma has received tentative approval from U.S. Food and Drug Administration (USFDA) for Erdafitinib, 3 mg, 4mg, and 5 mg, a generic version of Balversa by Janssen Biotech Inc. NATCO’s Erdafitinib is indicated for the treatment of adult patients with locally advanced unresectable or metastatic urothelial carcinoma harbouring susceptible FGFR3 genetic alterations who have disease progression during at least 1 line of prior therapy.
Erdafitinib tablets had estimated sales of around $60 million in the U.S. for 12 months ending September 2025 as per industry sales data.
Natco Pharma was promoted as a private company to be in the business of research, developing, manufacturing and marketing of pharmaceutical substances and finished dosage forms for Indian and International markets.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: